Add Yahoo as a preferred source to see more of our stories on Google. A 68-year-old Houston woman says she spent more than a year trying to find the source of water flowing into her backyard, only to ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

Having birched CSL shares by 5% yesterday, investors reacted by wiping a further 12% from the value of the stock. In total, that’s $16 billion of market cap, with CSL shares now at their lowest level ...

HOUSTON — A 68-year-old Houston woman says she spent more than a year trying to find the source of water flowing into her backyard, only to learn the leak may be coming from a business behind her home ...

Earnings call CSL reported H1 FY26 revenue of $8.3B (down 4% YoY, constant currency) and NPATA of $1.9B (down 7%). Reported NPAT fell 81% due to $1.05B in impairments. Despite challenges, full-year ...

The global biotechnology company announced minutes before the market closed on Tuesday that Mr McKenzie would be immediately replaced by Gordon Naylor, a current CSL director who has held a number of ...

CSL booked after-tax impairments of about $1.1 billion, largely related to intellectual property at its Vifor and Seqirus units, reflecting generic competition and lower demand for COVID-related ...

CSL Limited (CSL.AX) reported a significant 81% decline in net profit after tax for the first half of fiscal year 2026 due to one-off costs. The company’s revenue fell 4% to $8.3 billion, while gross ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

The global biotech has lost $36bn in market value and axed its CEO, yet its interim boss insists CSL remains a ‘blue chip’ company. Battling lower vaccination rates in the US under the Trump ...

SYDNEY, Feb 11 (Reuters) - CSL Ltd (CSL.AX), opens new tab on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, a day ...